Abstract | BACKGROUND: Donor-derived cell-free DNA (dd- cfDNA) is a useful biomarker of rejection that originates from allograft cells undergoing injury. Plasma levels <1% in kidney transplant recipients have a high negative predictive value for active allograft rejection. The utility of this biomarker in kidney transplant recipients receiving immune checkpoint inhibitor therapy is unknown. METHODS: We describe a case in which serial dd- cfDNA monitoring facilitated the use of immune checkpoint inhibitor therapy, which is known to be associated with high rates of rejection, in a kidney transplant recipient with metastatic cancer. RESULTS: CONCLUSIONS:
|
Authors | Laila Lakhani, Sami Alasfar, Anshul Bhalla, Amtul Aala, Avi Rosenberg, Darin Ostrander, Megan D Schollenberger, Daniel C Brennan, Evan J Lipson |
Journal | Transplantation direct
(Transplant Direct)
Vol. 7
Issue 2
Pg. e656
(Feb 2021)
ISSN: 2373-8731 [Print] United States |
PMID | 33490381
(Publication Type: Journal Article)
|
Copyright | Copyright © 2021 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc. |